M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B BioPharma DiveThe buyout hands J J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.OncologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) BioPharma Dive The buyout hands J J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionNext: Pfizer’s Hympavzi secures FDA expanded indications for haemophilia Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
